REGENXBIO - 51 Year Dividend History | RGNX

Historical dividend payout and yield for REGENXBIO (RGNX) since 1971. The current TTM dividend payout for REGENXBIO (RGNX) as of January 20, 2022 is $0.00. The current dividend yield for REGENXBIO as of January 20, 2022 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.119B $0.155B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio